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Cytotoxic Tlymphocytes(CTL) recognizeviral antigens in association withclass
I molecules of the MHC (1). Recent work has shown that the epitopes of proteins
recognized by class I MHC-restricted CTL can be defined in the lysis assay with
short synthetic peptides (2-8). In addition, target cellsthat expressrapidlydegraded
fragments ofviral proteins, which are not detectable serologically at the cell surface,
are recognized efficiently by CTL (9-11). These results are consistent with the con-
cept that class I-restrictedCTL recognize protein antigens onlyafter theyhave been
degraded in the cytoplasm ofthecell in which theyare synthesized(10), or intowhich
they have entered byfusion ofvirus with an endosome membrane (12-14). However,
thepathways bywhich peptide epitopes are generated and transported to thesurface
of an infected or transfected cell are not known.
Additional evidence that expression of an intact viral protein at the surface of
a target cell is not by itself sufficient for recognition by CTL has arisen from work
withvaccinia virus as avector for the expression ofinfluenzahemagglutinin. While
comparingearly (E) (active before viral DNA replication) withlate (L) (active after
DNA replication) vacciniapromoters forexpressionofinfluenza hemagglutinin (HA),
Coupar et al. (15) found that despite the presence of serologically detectable HA
at the cell surface, presentation ofHA epitopes to CTL was inhibited during the
late phase of vaccinia infection.
In thispaper, we extend these results by showing that the vaccinia-induced defect
in presentation ofinfluenza antigens exists in a less profound form during the early
phaseofinfection, is selective forcertain epitopes, and can be overcome by manipu-
lations that induce enhanced degradation ofthe influenza protein in the vaccinia-
infected cell. These results emphasize the association between degradation of
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endogenously synthesized antigens in the cytoplasm with recognition by class I-re-
stricted CTL of epitopes at the cell surface. In addition, the specificity of the vac-
cinia inhibitory effect suggests diversity in the mechanisms by which different epi-
topes are presented at the cell surface in association with class I molecules.
Materials and Methods
Mice.
￿
3-6-mo-old C57BL/10 or CBA mice used as responding cell donors were obtained
from the National Institute for Medical Research, London, U.K., or the Sir William Dunn
School of Pathology, Oxford, U.K.
In Vivo Priming ofMice.
￿
Mice were anesthetized with ether and primed by intranasal in-
fection with five haemagglutinin units (HAU) of E61-13-H17 influenza virus as infectious
allantoic fluid diluted in 50 al PBS (16), or by intravenous injection of 10' PFU recombinant
HlVAC, 7 .5K as described (17).
Peptides.
￿
Peptides were synthesized by solid phase techniques on a peptide synthesizer
(430A; Applied Biosystems, Inc., Foster City, CA) as described (2), and were kindly supplied
by Jonathan Rothbard (Imperial Cancer Research Fund).
Recombinant Vaccinia Viruses: Hemagglutinin.
￿
The construction of a vaccinia-expressing
influenza HA of the Hl subtype derived from A/PR/8/34 under the control of the 7 .5K pro-
moter (H1VAC, 7.5K) has been described previously (18). Deletion of the NH2-terminal
signal sequence from the HA cDNA (amino acids 2-17, inclusive) has also been described
(11). The signal-deleted Hl mutant and full length Hl cDNA were cloned into the vaccinia
expression plasmid pRK19 (R. Kent and G. Smith, manuscript in preparation) downstream
of the 4B late promoter. The derived recombinant vaccinia were termined Sig-H1VAC 4B
and Hl VAC 4B, respectively.
Recombinant Vaccinia Viruses: Nucleoprotein (NP).
￿
A full length cDNA copy ofRNA segment
5 from influenza A/NT/60/68 (19) was cloned into the vaccinia expression plasmid PSCll
downstream of the 7 .5K promoter (20), or the plasmids pRK19 and pKB14 (K. Breckling
and B. Moss, manuscript in preparation) downstream of the 4B and 11K promoters, respec-
tively. The derived recombinant vaccinia were termed NP-VAC 7 .5K, NP-VAC 4B, and NP-
VAC 11K, respectively.
The deletion mutant (IMP 1295) of NP coding for amino acids 1, 2, 327-498 was cloned
as a partial Hind III 879-bp fragment of the plasmid pTK IMP1295 (21) into the Hinc II
site of pUC9. The desired sequence was removed from this plasmid (pUC9 IMP1295) as
a 595-bp (Bam HI) fragment and cloned into the vaccinia expression plasmids PSCll (7 .5K
promoter), pRK19 (4B promoter), or pKB14 (11K promoter) as described above. The derived
recombinant vaccinia were termed IMP1295VAC 7.5K, IMP1295VAC 4B, and IMP1295-
VAC 11K, respectively.
The design of the ubiquitin(Ub)-NP fusions was based on the work of Bachmair et al.
(22). The murine Ub gene was kindly provided by Dr. Tom St. John (Fred Hutchinson Cancer
Research Center) as an Eco RI fragment (arf2, reference 23) subcloned into the plasmid
pSJ118. The Ub cDNA was subcloned as a 319-bp Eco RI fragment into the Eco RI site of
M13mp18AM4. A Sal I site was introduced into the sequence ofthe arf2 such that the central
three bases ofthe Sal I site formed an Arg codon (CGA) immediately following the terminal
Gly codon of Ub. The DNA sequence coding for the terminal 2 glycines of Ub in arf2 read
GGT (Gly) GGC (Gly) ATC (Ile) ATT (Ile) before mutagenesis and GGT (Gly) GGT (Gly)
CGA (Arg) CTT (Leu) after. The sequence of the mutagenic oligonucleotide was GCGTCT-
GCGCGGTGGTCGACTTGAGCCATCCCTTCG, and mutagenesis employed a standard
procedure using amber selection in M13 as described (24). The complete mutated arf2 cDNA
was sequenced by the dideoxy method. The full length NP cDNA (19) with an Nco I restric-
tion site (CCATGG) at the start of translation was kindly provided by Ian Jones (NERC
Institute for Virology, Oxford). The full length NP cDNA was cloned between the Nco I
and Sal I sites of the plasmid pTAC-85 (25). The Ub-Arg-NP fusion was obtained as follows.
pTAC-85-NP was digested with Nco I, and the ends blunted with mung bean nuclease using
the buffers described (26) and 3 U ofnuclease (Pharmacia Fine Chemicals, Piscataway, NJ)
to digest 5 ug of DNA in 100 41. The mutated Ub cDNA in M13 was digested with Sal I,TOWNSEND ET AL.
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and the ends filled in with the Klenow fragment of DNA polymerase using standard proce-
dures. The Ub cDNA was then isolated afterEco RI digestion. The Nco I cut, nuclease treated,
ptac-85-NP was digested with Eco RI, and the fragment containing the NP sequence isolated
and ligated to the prepared Ub cDNA fragment. The resulting plasmid contained the com-
plete Ub sequence fused to nucleoprotein with an Arg codon replacing the Met codon of
NP The Ub-Met-NP fusion was obtained by following the same procedures but treating
the Sal I cut Ub cDNA in M13 with Mung Bean nuclease, and the Nco I cut NP by filling
in with the Klenow fragment of DNA polymerase. The resulting fusion retained the ATG
codon of NP fused to the terminal Gly codon of Ub. The sequence ofthe fused regions were
confirmed by dideoxy sequencing. The cDNA coding for the two Ub-NP fusions were sub-
cloned as 2041-bp Eco RI-Sal I fragments into the vaccinia expression plasmids PSC11 (7.5K
promoter), pRK19 (4B promoter), and pKB14 (11K promoter) as described above. The de-
rived recombinant vaccinia were termed Ub-Arg-NP-VAC 7.5K, Ub-Arg-NP-VAC 4B, Ub-
Arg-NP-VAC 11K, Ub-Met-NP-VAC 7.5K, Ub-Met-NP-VAC 4B, and Ub-Met-NP-VAC 11K.
Insertion into the vaccinia tk gene, isolation, and purification of recombinant viruses fol-
lowed standard procedures (27).
Immunoprecipitation.
￿
The technique used has been described in detail elsewhere (10, 11).
Briefly, for Fig. 1, 5 x 106 murine L929 cells were infected with vaccinia viruses at 20 plaque-
forming units (PFU) per cell or with A/PR/8/34 influenza virus for 2 h at 37'C. Cells were
washed once and resuspended at 106 cells per ml in complete medium. After incubation at
37°C for 7 h, cells were washed and incubated in methionine-free medium for 1 h. Cells
were spun down, resuspended in 200 gl of methionine-free medium, and labeled with 120
gCi of [35S]methionine for 30 min at 37°C. Cells were then diluted with 5 ml of complete
medium containing 4 mM methionine, and the first sample (106 cells) was removed for lysis.
The remaining cells were incubated, and further samples removed after 1 and 4 h. Samples
were processed as described previously (10) using the mAb H36-18-2 for immunoprecipita-
tion, and resolved on a 10% gel.
L/Db cells were infected with recombinant vaccinia expressing full length NP at 5 PFU
per cell and those expressing the IMP fragment at 7 PFU per cell for 90 min (Fig. 3). They
were then washed once with PBS and resuspended at 1-2 x 106 cells per ml in complete
medium. Cells infected with vaccinia expressing inserts from the 7 .5K promoter were in-
cubated for 2 h, those infected with vaccinia expressing inserts from the 4B promoter were
incubated for 5 h. The cells were then washed twice in PBS and resuspended in 0.5 ml of
methionine-free RPMI 1640/5% FCS and incubated for a further hour before addition of
227 gCi of ["S]methionine and further incubation for 30 min. Cells were then diluted with
3 ml of complete medium containing 4 MMol L-methionine. The first sample of cells (2 x
106) was removed for lysis. The remaining cells were incubated, and further samples were
removed 30 and 120 min later. The samples were processed as described previously (10), with
the minor modification that the lysates were pre-absorbed with 100 Al of 10% Staphylococcus
aureus organism (Cambridge Bioscience, Cambridge, UK) overnight at VC. S146 antibody
was added for 1 h, and the samples were treated as previously described. The immunoprecipi-
tates were fractionated on a 1217o polyacrylamide gel in the presence of 2-ME. The gel was
fixed, treated with amplify (Amersham Corp., Bucks, UK), dried, and exposed to preflashed
x-ray film.
L/Db cells were infected with vaccinia expressing wild type NP, Ub-arg-NP, Ub-met-NP,
or the IMP1295 fragment (negative control) under the control of the 7 .5K promoter at 7
PFU per cell for 1.5 h washed in PBS, resuspended at 106 cells per ml in complete medium
for 3 h (Fig. 7). The procedure was then as described for Fig. 3, using the mAb to NP 5/1
(28), which does not bind the IMP1295 fragment.
Cytotoxic TCell Culturesand Clones.
￿
Polyclonal CBA (H2-k) CTL specific for peptide 50-63
were used. 3-6-mo-old female CBA mice were infected intranasally with 5 HAU of virus
E61-13-H17. At least 2 wk later, their spleen cells were restimulated in vitro with peptide.
Cultures were prepared as described previously (29), but the stimulator cells were treated
with peptide 50-63 at 1-5 x 10"
5 M/1 for 1 h instead of being infected with influenza virus.
Cultures initiated in this way (in the absence of exogenous IL-2) exhibited powerful peptide-
and virus-specific cytotoxic activity after5 d. CTL lineswere maintainedin exponential growth121 4 ANTIGEN DEGRADATION AND CYTOTOXIC T CELL RECOGNITION
by weekly stimulation with peptide-pulsed feeder cells and human rIL-2 (10 Cetus U/ml,
Cetus Corp., Emeryville, CA) .
Polyclonal CBA CTL Specificfor Hemagglutinin .
￿
CBA mice were primed with 10' PFU i .v.
of recombinant vaccinia expressing the HA ofA/PR/8/34 under the control of the 7.5K pro-
moter. 2 wk later spleen cells were restimulated in vitro with influenza virus A/PR/8/34 as
described (11, 17), followed by a second restimulation in vitro 7 d later. After culture for 5
more days, the cells were harvested and used in the cytotoxicity assay described below.
Clone F5 is specific for peptide 365-379 derived from the NP A/NT/60/68 and has been
described in detail previously (2) .
Cytotoxic Assay.
￿
A standard 6-h Cr'' release assay was used as described previously using
either L cells transfected with the class I gene H-2Db (10, 29) or untransfected L cells for
experiments with hemagglutinin-specific CTL . In comparisons of vaccinia expressing pro-
teins from early and late promoters, target cells were infected with 5-10 PFU per cell and
labeled with Cr51 simultaneously for 90 min . They were then washed twice in PBS,
resuspended at 10 6 per ml in complete medium for 4 h, and rewashed twice in PBS before
use in the cytotoxicity assay. The timing of contact between targets and T cells was therefore
comparable with the immunoprecipitation experiments . Percent-specific chromium release
was calculated as : (release by CTL - medium release) x 100/(2 .5% Triton release - medium
release) . All points were measured in duplicate against quadruplicate medium controls . Spon-
taneous Cry' release in the absence ofCTL ranged between 8% and 30% in all experiments.
Results
Influenza HA Expressedfrom the Vaccinia 4B (L) Promoter Is Inefficiently Recognized by
CTL . Coupar et al . (15) used the vaccinia 11K promoter to express recombinant
influenza A/PR/8/34 (Hl) hemagglutinin . To confirm these results, wemade a recom-
binant that expresses the sameHA gene under the late 4B promoter. Fig. 1 (lanes
1-3) shows the results of a pulse chase experiment confirming that serologically de-
tectableHA was synthesized in the recombinant vaccinia-infected target cells . Im-
munofluorescence staining confirmed that >80% of infected cells stained brightly
at the cell surface 6-8 h after infection, at levels comparable with a vaccinia expressing
theHA gene from the 7 .5K promoter (11), which functions both E and L (not shown) .
Hemagglutinin-specific cytotoxic T cells, raised as described in Materials and
Methods (11, 17), were tested for recognition oftarget cells infected with recombinant
vaccinia that expressed hemagglutinin under the control of either the 7.5K (E and
L) or 4B (L) promoters . Fig . 2 shows that whereas HA expressed under the control
FIGURE 1 .
￿
Immunoprecipitation and pulse chase ofHA (lanes
1-3) and SIG-HA (lanes 4-6) expressed from the 4B promoter.
Infected cells were pulse labeled for 30 min before removing
the first aliquot for immunoprecipitation (lanes 1 and 4), excess
unlabeled Met was added and further aliquots removed after
1 h (lanes 2 and 5) and 4 h (lanes 3 and 6) .N
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FIGURE 2.
￿
Deletion oftheHA signal sequence overcomes
the late defect in presentation of HA expressed from the
4B promoter. Recognition by hemagglutinin-specific poly-
clonal CBACTLofL929 target cells infected with (0)wild
type WRVAC; (*) HlVAC 7.5K; (M) Hl-VAC 413;
Sig-H1VAC 4B.
ofthevaccinia 7.5K promoter wasefficientlyrecognized (11, 17), target cells expressing
HA from the 4B promoter were lysed only marginally above the background on
wild type vaccinia-infected cells. Presentation of epitopes to HA-specific CTL ap-
peared to be inhibited in the target cells expressing HA under the control of the
4B (late promoter).
Deletion ofthe NH2-terminal Signal SequenceofHA Overcomes the Vaccinia-induced Block
to Presentation. In earlier work, we studied the presentation to CTL ofa deletion
mutant ofinfluenza A/PR/8/34 hemagglutinin that lacked an N112-terminal signal
sequence. Target cells that synthesized the signal deleted HA as a rapidly degraded
cytoplasmic protein did not express any serologically detectable HA at the cell sur-
face, but were recognized efficiently by class I-restricted CTL (11). These results
were consistent with CTL recognizing a degradation product ofthe HA molecule,
and were supported by experiments showing that the epitopes ofboth NP and HA
could be defined with short synthetic peptides in vitro (2, 4, 8, 30).
It was therefore of interest to see what effect deleting the signal sequence would
have on presentation of HA to CTL during the late phase ofvaccinia infection. A
new recombinant vaccinia was produced that expressed the signal-deleted HA (8)
underthe control ofthe 4B promoter. Fig. 1 (lanes 4-6) demonstrates thatthe signal-
deleted HA is detected as expected as a ti62-kD protein that shows no evidence of
glycosylation, and is more rapidly degraded than full length HA with a half life of
<1
￿
h (11,
￿
31).
HA-specific cytotoxic Tcells recognize target cells expressing the signal-deleted
HA under the control of the 4B promoter at least as efficiently as full length HA
expressed from the 7.5K promoter (Fig. 2). In contrast, target cells expressing the
fulllength HA from the 413 promoter were barely lysed above background. Deletion
ofthe N112-terminal signal sequence therefore restored presentation to CTL ofHA
epitopes expressed during the late phase of vaccinia infection.
Presentation ofNucleoprotein Epitopes IsSelectivelyInhibitedin Vaccinia-infected Cells.
￿
To
extend the results obtainedwithhemagglutinin, we examinedrecognitionofinfluenza
A/NT/60/68 nucleoprotein (NP) expressed under the control of the 7.5K (E and
L) and the 4B (L) and 11K (L) promoters. NP was expressed efficiently from each
promoter (Fig. 3 and data not shown). CTL specific for two different epitopes of
NP, definedwith peptides composed ofamino acids 50-63 (4) and 365-379(2), were
compared for recognition ofinfected target cells. The targets were L cells (H-2k)
transfected with the class I gene Db (10), so that presentation ofthe two epitopes,
restricted through Kk and D6 respectively, could be compared simultaneously.1216
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FIGURE 3 .
￿
Immunoprecipita-
tion and pulse chase _ of NP
(lanes 1-6) and the IMP1295
fragment (lanes 7-12) expressed
from the7.5K promoter (lanes
1-3and 7-9) and4B promoter
(lanes 4-6and10-12). Infected
cells were pulse labeled for 30
min before removing the first
aliquot for immunoprecipita-
tion (lanes 1, 4, 7, 10) ; excess
unlabeled Met was added and
further aliquots removed after
30 min (lanes 2, 5, 8, 11) and
120 min (lanes 3, 6, 9, 12) .
CTL cultures specific for the NH2-terminal epitope (50-63) recognized target
cells expressing NP from either the 7.5K or the 4B or 11K promoters as efficiently
as influenza-infected cells . In contrast, clone F5 or polyclonal cultures from H26
mice specific forpeptide 365-379 recognized the same target cells at alow or inter-
mediate level when NP was expressed from the 7.5K promoter, or not at all when
NP was expressed from the 4B or 11K promoters (Fig . 4 and data not shown) .
These results showed that despite a high level of synthesis of the complete
nucleoprotein in thetarget cells(Fig. 3),-therewas amarked disparity in the efficiency
with which the two epitopes from different sites in the protein were presented to
CTL in vaccinia-infected cells. Presentation of the Db restricted epitope 365-379
was selectively inhibited to an intermediate extent when NP was expressed from
the 7.5Kpromoter, andprofoundly when expressed from the4B or 11KLpromoters .
In contrast, theKk-restricted epitope 50-63 was presented efficiently both early and
late in vaccinia infection .
Enhanced Degradation ofNP Partially Overcomes the Vaccinia-induced Block to Presenta-
tion . We produced tworapidly degraded derivatives ofnucleoprotein that contained
the COOH-terminal epitope 365-379. The first was a deletion mutant of NP
(IMP1295, references 10, 21)that expressed amino acids 1, 2, 328-498(lackingamino
acids 3-327 inclusive) . The second was based on the observations of Bachmair et
al . (22) that a full length protein with certain amino acids replacing its NH2-
terminal methionine, when fused to Ub, was rapidly degraded in yeast cells (Sac-
charomyces cerevisiae) . They termed this effect of the NH2-terminal amino acid on pro-
tein stability the "N-end rule".
Expression oftheRapidly Degraded COOH-terminalFragment ofNP Overcomes the Defect
in Antigen Presentation Associated with Vaccinia Infection . Theexpression ofthe deletion
mutant (IMP1295)of influenzaNP (amino acids 1, 2, 328-498) in Xenopus Oocyes
and transfected L cells has previously been described (10, 21). L cells transfected
with thefragment were recognized efficiently by CTL, despite the fact that the level
of protein expressed was too low to detect by immunoprecipitation (10) .y
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FIGURE 4.
￿
(A) Selective presentation (E)
of NP epitopes expressed from the 7.5K
vaccinia promoter. Recognition by clone
F5 (specific for 365-379 + Db) of L/Db
target cells: (CI) uninfected; (A) infected
with E61-13-H17 influenza virus; (M)NP-
VAC 7.5K. Recognition by CBA CTL
(specific for 50-63 + Kk) of the same
target cells: (0) uninfected; (+) infected
with E61-13-H17 influenza virus; (+)NP-
VAC 7 .5K. (B) Selective presentation (L)
of NP epitopes expressed from the4B vac-
cinia promoter. Symbols as for (A).
Vaccinia expressing the fragment under the control of the 7.5K (E and L) and
4B (L) promoters were compared for expression. Fig. 3 shows that the fragment
was synthesized in sufficient quantity from both promoters to be detected by immu-
noprecipitation with apolyclonal sheep serum. The molecularmass assessed by PAGE
appeared slightly higher (22 kD) than the expected molecularmass of 19.2 kD (the
significance of this finding is not clear). Lanes 7-9 and 10-12of Fig. 3 demonstrate
that the fragment was expressedin greater quantity from the 4B than the 7.5K pro-
moter. In both cases, the fragment was short lived, with a half life of <30 min.
The effect on CTL recognition is shown in Figs. 5 and 6. The incomplete block
to presentation of the epitope 365-379 detected during the early phase of vaccinia
infection (7.5Kpromoter) is overcome by expressing it as part ofthe short lived frag-
ment (Fig. 5). The profound block detected during the late phase (4B promoter)
was also overcome, but the level oflysis of target cells expressing the fragment from
the 4B promoter was always less than when it wasexpressed from the 7.5K promoter
(Fig. 6).
Antigen Presentation andthe N-endRule.
￿
Two fusion proteins were produced by ligating
the cDNA sequences coding for murine Ub (21) to the A/NT/60/68 influenza NP
(19). In the first (control), the complete Ub was fused to the NH2-terminal methio-
nine of NP (Ub-met-NP). In the second, the NH2-terminal methionine codon of
NP was replaced by an arginine codon to produce Ub-arg-NP The two fusion pro-
teins therefore differed by a single amino acid (met/arg) at the NH2 terminus of
the NP sequence.
The two fusion proteins were expressed under the control of either the 7.5K (E
plus L) or 4B (L) or 11K (L) vaccinia promoters. Fig. 7 compares the stability and
level of expression of wild type NP (lanes 1-3) with the Ub-arg-NP (lanes 4-6) and
the Ub-met-NP control (lanes 7-9), expressed under the control of the 7.5K pro-1218
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FIGURE 5 .
￿
Expression of short-lived IMP1295 fragment
from the 7.5K promoter overcomes the early defect in pre-
sentation of NP. (A) Recognition by clone F5 (specific for
365-379 + Db) of L/Db target cells: (0) uninfected ; (/)
infected with NPVAC 7.5K; (*) IMP1295VAC 7.5K . (B)
Recognition byCBA CTL (specific for 50-63 + Kk) of the
same set of L/Db target cells . Symbols as in (A) .
moter. The apparent molecular masses of the two fusion proteins was the same as
for wild type NP (N56 kD) . This implied that they were cleaved at the Ub-NPjunc-
tion rapidly after synthesis, and agrees with the results obtained by Bachmair et
al . (22) using Ub-R-galactosidase fusions in yeast . The NP component of the Ub-
FIGURE 6 .
￿
Expression of short-lived IMP1295 fragment or
Ub-Arg-NP fusion protein partially overcomes the late de-
fect in presentation ofNP expressed from the 4B promoter.
(A) Recognition by clone F5 (specific for 365-379 + Db)
of L/Db target cells : (O) uninfected; (/) infected with NP-
VAC 413 ; (*)Ub-Met-NPVAC 411 ; (®)Ub-Arg-NPVAC
413 ; (A) IMP1295VAC 4B; (X)IMP1295VAC 7.5K (posi-
tive control for clone F5). (B) Recognition by CBACTL
(specific for 50-63 + Kk) of the same set of target cells .
Symbols as in (A).TOWNSEND ET AL .
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FIGURE 7 . Immunoprecipitation and
pulse chase ofNP (lanes 1-3),Ub-Arg-NP
(lanes 3-6), Ub-Met-NP (lanes 7-9), and
a negative control (lanes 10-12), expressed
from the 7.5K promoter. Infected L/Db
cells were pulsed labeled for 30 min be-
fore removing the first aliquot forimmu-
noprecipitation (lanes 1, 4, 7, 10), excess
unlabeledMetwasaddedand further ali-
quots removed after 30 min (lanes 2, 5,
8, 11) and 120 min (lanes 3, 6, 9, 12) .
arg-NP fusion was degraded rapidly, the halflife being <30 min (Fig . 7, lanes 4-6) .
In contrast, the half life of theNP component ofthe Ub-met-NP fusion (lanes 7-9)
was not detectably different from the wild type NP, which was stable during the
2-h duration of the pulse chase experiment . The same Ub-NP fusion proteins ex-
pressed under the control of the 4B or 11K late promoters were made in greater
quantity, but decayed at the same rates as for the 7.5K promoter (data not shown) .
These results confirm those of Bachmair et al . and extend the applicability of the
N-endrule to proteins expressed from vaccinia promoters in thehigher eukaryotic cell .
Fig . 8 compares recognition of target cells expressing wild type NP, the Ub-met-
NP, and the Ub-arg-NP fusions from the vaccinia 7.5K promoter . L/Db target cells
expressing full length NP andthetwoUb-NPfusion proteins were recognized equally
efficiently by CBAT cells specific for peptide 50-63. This showed that rapid degra-
dation did not impair presentation of the epitope defined by the sequence 50-63.
In contrast, recognition by clone F5, specific for residues 365-379, of vaccinia in-
fected cells expressing the full length NP was impaired (as shown above) . However,
target cells expressing the rapidly degraded Ub-arg-NP fusion were recognized to
a level approaching that of influenza-infected target cells (Fig . 8 A) . In four out of
six repeats ofthis experiment, the control Ub-met-NP fusion wasrecognized by clone
F5 indistinguishably from thewild type NP (asin Fig . 8A). However, in two experi-
ments recognition was at an intermediate level between wild type NP and the rap-
idly degraded Ub-arg-NP (data not shown) .
The effect of these manipulations on presentation during the late phase (4B pro-
moter) are shown in Fig . 6. Again theNP epitope 50-63 recognized by CBAT cells
was readily detected on target cells expressing either wild type NP or either of the
Ub-NP fusion proteins . In contrast, the epitope defined with clone F5, 365-379,
appeared to be completely absent from the surface ofthe same target cellsexpressing
either wild type NP or theUb-met-NP fusion . Cells expressing the rapidlydegraded
ub-arg-NP fusion were recognized by clone F5, but at a level well below thepositive
control (Fig. 6) .1220
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FIGURE 8 .
￿
Expression of the short-lived Ub-Arg-NP fu-
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presentation ofNP. (A) Recognition by clone F5 (specific
for 365-379 + Db) of L/Db target cells : (p) uninfected;
(/) infected with NP-VAC 7.5K ; (®) Ub-Arg-NP-VAC
g
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7.5K ; (*) Ub-Met-NPVAC 7.5K ; (A) influenza E61-13-
H17 . (B) Recognition by CBACTL (specific for 50-63 +
Kk) of the same set of L/Db target cells . Symbols as in (A).
10 :1 5 :1 2.5 :1 1 .2 :1
K:T
These results show that rapid degradation of NP induced by fusion to ubiquitin
and mutation of the NH2-terminal met to arg can partially overcome the profound
block to presentation of theepitope 365-379 during thelate phase ofvaccinia infec-
tion . The incomplete block detected during the early phase (using the 7.5K pro-
moter) was correspondingly more easily reversed .
Discussion
Coupar et al. (15) reported that late in vaccinia virus-infected cells there is a de-
fect in presentation of epitopes to class I MHC-restricted CTL. We have extended
these observations, showing that there is also a less profound defect in presentation
early in vaccinia infected cells, andthat neither defect is universal or absolute. Factors
whichmay influence presentation of antigens to CTL include the subcellular local-
ization of antigen, rate of proteolytic degradation, and efficiency of transport to the
cell surface in association with a class IMHC molecule. The vaccinia-induced de-
fect in antigen presentation may occur at any of these stages .
The enhanced recognition ofHA lacking a signal sequence (Fig . 2) could be at-
tributed to either altered location in the cell, or increased rate of degradation . The
NH2-terminal signal sequence of HA is required for transfer of the molecule
through the membrane of the rough endoplasmic reticulum (ER), and its subse-
quent glycosylation, folding, trimerisation, and transport to the cell surface as an
integral membrane protein (31) . Preventing entry into the endoplasmic reticulum,
by deleting the signal sequence, wouldbe expected to increase the number of incor-
rectly folded molecules resident in the cytoplasm available as substrates for cyto-
plasmic proteases. The result emphasizes that signal-dependent transfer of viralpro-
teins across the membrane of the ER does not play a role in presentation ofHA
epitopes to class I-restricted CTL.TOWNSEND ET AL.
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Expression of nucleoprotein from a late vaccinia promoter is associated with an
increase in the level of NP synthesis compared with the 7.5K promoter (Fig. 3).
This establishes that the blockto presentation of the 365-379 epitope is not related
to the amount ofcomplete NP available in thetarget cell. Either ofthe two strategies
used to destabilize themolecule resulted in partialrestoration of presentation without
altering subcellular location as detected by immunofluorescence (21, and data not
shown). This shows that degradation ofNP and recognitionby CTL ofthe sequence
365-379 are linked.
Evidence is accumulating forthe general statement that CTL recognizethe degra-
dation products of viral proteins, rather than the folded proteins themselves (2-11).
It is possible that vaccinia infection interferes with specific degradative enzymes in-
volved in the generation of the immunodominant peptide epitopes of HA and the
365-379 epitope of NP, but has no effect on the generation of 50-63. Recently, se-
quences have been identified in cowpox and fowlpox viruses that are homologous
to a family of eukaryotic serine protease inhibitors (32, 33). The cowpox protein
had no identifiable hydrophobic signal sequence, and so would be expected to ac-
cumulate in the infected cytoplasm where it could inhibit specific proteases of the
host cell. However, it is not yet known whether vaccinia, which is a closely related
pox virus (34), can express an equivalent protein.
The enzymesinvolved in thedegradationof the shortlived proteins described here
have not been identified. In yeast, the rapid degradation of a fusion between Ub
and R-galactosidase was associated with polyubiquitination of the R-galactosidase,
implying arole for the Ub-dependent degradative pathway (22). An alternative ex-
planation forthe N-end effect on NP is that the presence of an arginine at the free
NH2 terminus rather than acting as a specific signal for degradation, interferes with
folding and results in the exposure of proteolytic cleavage sites that would normally
be protected. From this point of view, the N-end effect on NP may be analogous
to deleting the signal sequence of HA or deleting a large segment of NP, both of
which are expected to interfere with folding. Work is in progress to assess the role
of the Ub-activating enzyme in the degradation of our three short-lived proteins
in the temperature-sensitive cell line ts85 (35).
The third stage ofpresentation suggestedaboveis transportof thepeptide epitope
to thecell surface in association with aclass I molecule. It is not known how peptides
cross a bilipid membrane to reach the cell surface, nor where in the infected cell
they associate with class I molecules. Vaccinia infection is associated with almost
complete inhibition of host protein synthesis (34). It is therefore possible that lack
of synthesis of class I molecules may contribute to the loss of presentation during
the late phase of vaccinia infection, as suggested by Coupar et al. (15). We have ob-
served that late during infection with vaccinia, target cells can be sensitized over
the expected dose range with peptide 365-379 added to the medium surrounding
the cells (2, 4, and data not shown). This shows that vaccinia infection does not in-
terfere with the peptide-presenting function of Db class I molecules at the cell sur-
face. However, ifpeptides generated in the infected cell associate predominantlywith
newly synthesized class I molecules, en route to the surface from the endoplasmic
reticulum, this explanationforour results couldstillbe consistent. Thepositive effects
ofenhanced antigendegradationcould then be explained by an increase in the con-
centration ofpeptide ligand available forbinding to limiting concentrations of class1222
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I molecules. The apparent specificity of the inhibitory effect may relate to differ-
ences in rates oftransport of class I molecules (36) or rates of association of peptides.
Coexpression of class I molecules and viral proteins from late vaccinia promoters
will shed light on the issue.
Summary
Vaccinia infection interferes with the presentation of influenza Haemagglutinin
(HA) and Nucleoprotein (NP) to class I-restricted CTL. The inhibitory effect is
selective for certain epitopes, and is more profound during the late phase of infec-
tion. For influenza A/NT/60/68 NP, the block is present during both early and late
phases ofinfection, and is selective for the C0011-terminal epitope defined by pep-
tide 366-379, having no detectable effect on the presentation of the NH2-terminal
epitope 50-63. The presentation of HA is inhibited only during the late phase of
vaccinia infection. For both proteins, presentation is partially (NP) or completely
(HA) restored by expression of rapidly degraded protein fragments in the vaccinia
infected target cell. For HA, deletion of the NH2-terminal signal sequence com-
pletely overcomes the block. For NP, either a large NH2-terminal deletion or the
construction of a rapidly degraded ubiquitin-NP fusion protein partially restores
presentation. These results illustrate the relationship between degradation of viral
proteins in the cytoplasm of an infected cell and recognition of epitopes at the cell
surface by class I-restricted T cells.
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